Pharmacokinetics and Pharmacodynamics of Tenecteplase: Results from a Phase II Study in Patients with Acute Myocardial Infarction
暂无分享,去创建一个
E. Braunwald | C. Cannon | F. Werf | N. Fox | P. Tanswell | N. Modi | F. Clow
[1] F. Verheugt. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. , 1997, The New England journal of medicine.
[2] E. Seifried,et al. Pharmacokinetics and Haemostatic Status During Consecutive Infusions of Recom binant Tissue-Type Plasminogen Activator in Patients with Acute Myocardial Infarction , 1989, Thrombosis and Haemostasis.
[3] The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. , 1993, The New England journal of medicine.
[4] B. Keyt,et al. A Long‐Half‐life and Fibrin‐Specific Form of Tissue Plasminogen Activator in Rabbit Models of Embolic Stroke and Peripheral Bleeding , 1994, Stroke.
[5] E. Seifried,et al. Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction. , 1989, The American journal of cardiology.
[6] R. Giugliano,et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. , 1998, Circulation.
[7] C. Wilson,et al. Effectiveness of double bolus alteplase in the treatment of acute myocardial infarction. , 1991, The American journal of cardiology.
[8] E. Braunwald,et al. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators. , 1999, American heart journal.
[9] B. Keyt,et al. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. , 1995, Circulation.
[10] E. Braunwald. The open-artery theory is alive and well--again. , 1993, The New England journal of medicine.
[11] Frans Van de Werf,et al. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.
[12] T. Investigators,et al. A comparison of reteplase with alteplase for acute myocardial infarction , 1997 .
[13] F. Werf. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial , 1999, The Lancet.
[14] D. Botstein,et al. A faster-acting and more potent form of tissue plasminogen activator. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[15] D. McTavish,et al. Reteplase. A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction. , 1996, Drugs.
[16] H. S. Mueller,et al. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.
[17] E. Braunwald,et al. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. , 1997, Circulation.
[18] T. W. Love,et al. An angiographic assessment of alteplase: double-bolus and front-loaded infusion regimens in myocardial infarction. DouBLE Study Investigators. Double Bolus Lysis Efficacy. , 1998, American heart journal.
[19] F. Werf. A Comparison of Continuous Infusion of Alteplase with Double-Bolus Administration for Acute Myocardial Infarction , 1998 .
[20] C. Wilson,et al. Efficacy of 100 mg of double-bolus alteplase in achieving complete perfusion in the treatment of acute myocardial infarction. , 1994, Journal of the American College of Cardiology.
[21] T. Senn,et al. Pharmacokinetics and pharmacodynamics of recombinant tissue‐type plasminogen activator following intravenous administration in rabbits: a comparison of three dosing regimens , 1998, Biopharmaceutics & drug disposition.
[22] T. W. Love,et al. Pharmacokinetics of a Slower Clearing Tissue Plasminogen Activator Variant, TNK-tPA, in Patients with Acute Myocardial Infarction , 1998, Thrombosis and Haemostasis.
[23] J. Wójcik,et al. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. , 1992, Journal of the American College of Cardiology.
[24] I. Palacios,et al. Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. , 1986, Circulation.